World's Best Scientists 2026 revealed!
Ayalew Tefferi

Ayalew Tefferi

Award Badge
Best Scientists
2025

D-Index & Metrics

Best Scientists

D-Index
174
Citations
121856
World Ranking
745
National Ranking
459

Medicine

D-Index
175
Citations
126647
World Ranking
430
National Ranking
259

Ayalew Tefferi publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ayalew Tefferi sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,651 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ayalew Tefferi D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ayalew Tefferi sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 175 D-Index — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2025 - Research.com Best Scientists Award

Overview

Ayalew Tefferi is affiliated with Mayo Clinic in the United States and has a significant research presence spanning multiple subfields of medicine, with a primary focus on hematology. Their work also covers genetics, molecular biology, rheumatology, and oncology, contributing broadly to medical science.

Their research topics include:

  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Eosinophilic Disorders and Syndromes
  • Kruppel-like factors research
  • Hemoglobinopathies and Related Disorders
  • Chronic Lymphocytic Leukemia Research

Tefferi's publication record spans several influential journals, with the most frequent venues being:

  • American Journal of Hematology
  • Blood
  • Blood Cancer Journal
  • Haematologica
  • British Journal of Haematology

Notable recent papers include:

  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data (2022, Blood)
  • Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management (2020, American Journal of Hematology)
  • Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management (2023, American Journal of Hematology)
  • Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera (2020, British Journal of Haematology)
  • Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia (2022, Blood)

The scientist collaborates frequently with other researchers, with notable coauthors including:

  • Naseema Gangat
  • Mrinal M. Patnaik
  • Animesh Pardanani
  • Aref Al-Kali
  • Mark R. Litzow

Their work largely contributes to understanding diagnostic and therapeutic strategies in myeloid neoplasms and leukemias, integrating clinical, genomic, and morphologic data. Tefferi's research output encompasses a substantial number of publications, reflecting sustained contributions to advancing hematological science.

Best Publications

  • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

    James W. Vardiman;Jüergen Thiele;Daniel A. Arber;Richard D. Brunning

  • Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

    Ross L. Levine;Ross L. Levine;Martha Wadleigh;Jan Cools;Benjamin L. Ebert;Benjamin L. Ebert

  • A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

    Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover

  • Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis

    Srdan Verstovsek;Hagop Kantarjian;Ruben A. Mesa;Animesh D. Pardanani

  • New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

    Francisco Cervantes;Brigitte Dupriez;Arturo Pereira;Francesco Passamonti

  • Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

    A Tefferi;J W Vardiman

  • MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

    Animesh D. Pardanani;Ross L. Levine;Terra Lasho;Yana Pikman

  • DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

    Naseema Gangat;Domenica Caramazza;Rakhee Vaidya;Geeta George

  • Myelofibrosis with myeloid metaplasia.

    Ayalew Tefferi

  • Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

    Tiziano Barbui;Giovanni Barosi;Gunnar Birgegard;Francisco Cervantes

  • Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

    Ayalew Tefferi;Juergen Thiele;Attilio Orazi;Hans Michael Kvasnicka

  • Mutations and prognosis in primary myelofibrosis

    Alessandro Maria Vannucchi;Tl Lasho;Paola Guglielmelli;Flavia Biamonte

  • A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

    Francesco Passamonti;Francisco Cervantes;Alessandro Maria Vannucchi;Enrica Morra

  • Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study

    A Tefferi;E Rumi;G Finazzi;H Gisslinger

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Long-term survival and blast transformation in molecularly-annotated essential thrombocythemia, polycythemia vera and myelofibrosis

    Ayalew Tefferi;Paola Guglielmelli;Dirk R. Larson;Christy Finke

  • Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

    Ross L. Levine;Animesh Pardanani;Ayalew Tefferi;D. Gary Gilliland

  • Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2 , MPL , TET2 , ASXL1 , CBL , IDH and IKZF1

    A Tefferi

  • Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)

    Tiziano Barbui;Guido Finazzi;Alessandra Carobbio;Juergen Thiele

  • CALR vs JAK2 vs MPL -mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

    A Tefferi;T L Lasho;C M Finke;R A Knudson

Frequent Co-Authors

Terra L. Lasho
Terra L. Lasho Mayo Clinic
Curtis A. Hanson
Curtis A. Hanson Mayo Clinic
Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Alessandro M. Vannucchi
Alessandro M. Vannucchi University of Florence
Mark R. Litzow
Mark R. Litzow Mayo Clinic
Tiziano Barbui
Tiziano Barbui FROM-Fondazione per la Ricerca Ospedale di Bergamo
David P. Steensma
David P. Steensma Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean becoming a doctor. The healthcare field offers many rewarding pathways that can start online or at schools with more flexible admission requirements. If you’re interested in advanced nursing roles but don’t yet have a nursing license, there are online direct entry msn programs for non-nurses that allow career changers to earn a Master of Science in Nursing quickly, setting a solid foundation for roles in clinical or leadership settings.

For those looking for accessible programs, consider nursing schools with high acceptance rates. These schools make entering the nursing profession more feasible, especially if you’re concerned about competitive admissions.

If direct patient care isn’t your ideal path, you could explore online medical coding classes with financial aid. This route opens doors to administrative healthcare positions and often offers flexible study options.

Prospective Licensed Practical Nurses can also benefit from finding an lpn program without teas test, removing barriers that might keep you from starting your nursing journey.

Best Scientists Citing Ayalew Tefferi

Trending Scientists

Recently Published Articles